Atlas Trials

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Clinical trial NCT05433285 · COMPLETED

Trial details

NCT number
NCT05433285
Sponsor
PT Bio Farma
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2022-06-07
Primary completion
2022-08-05
Enrollment
4050

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.